Literature DB >> 6581776

Alteration in prostacyclin and prostaglandin E2 production. Correlation with changes in human aortic atherosclerotic disease.

P H Rolland, R Jouve, E Pellegrin, C Mercier, A Serradimigni.   

Abstract

Prostacyclin (PGI2) and prostaglandin E2 (PGE2) production was investigated in human aortas (five controls and 27 with atherosclerotic lesions). The specific activities of PGI2 and PGE2 synthetase were studied using radioimmunoassays of PGE2 and 6-keto-PGE1 alpha of aortic microsomes incubated in the presence of additional substrate and cofactors. The atherosclerotic lesions were examined under the light microscope and were classified as Stage 1 when the disease was restricted to the intima and as Stages 2 and 3 when there were moderate or advanced lesions. Prostaglandin production for the control group (n = 5), Stage 1 (n = 7), Stage 2 (n = 10), and Stage 3 (n = 10) were as follows: 454 +/- 15, 162 +/- 81, 92 +/- 90, and 65 +/- 61 pmol 6-K-PGF1 alpha/50 mg protein/10 minutes; and 15 +/- 12, 399 +/- 406, 227 +/- 174, and 366 +/- 362 pmol PGE2/50 mg protein/10 minutes (mean +/- SD) respectively. We conclude that: 1) In normal aortas, PGE2 production was low, while PGI2 synthesis activity was elevated. The reverse situation was observed in aortas with atherosclerosis lesions (p less than 0.05). 2) There was an inverse relationship between PGE2 and PGI1 production (p less than 0.05). 3) There was a direct histologic relationship between lower PGI2 production and atherosclerosis progression. A decided decline in 6-K-PGF1 alpha production was detected in aortas in the early stages (65% of control values). 4) By contrast, a progressive increase in PGE2 production was found in Stage 2 and Stage 3 groups (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6581776     DOI: 10.1161/01.atv.4.1.70

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  10 in total

Review 1.  Vascular aging: chronic oxidative stress and impairment of redox signaling-consequences for vascular homeostasis and disease.

Authors:  Markus M Bachschmid; Stefan Schildknecht; Reiko Matsui; Rebecca Zee; Dagmar Haeussler; Richard A Cohen; David Pimental; Bernd van der Loo
Journal:  Ann Med       Date:  2012-03-01       Impact factor: 4.709

Review 2.  Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk.

Authors:  Francesco Cipollone; Maria Luigia Fazia
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

Review 3.  Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases.

Authors:  Eva H C Tang; Peter Libby; Paul M Vanhoutte; Aimin Xu
Journal:  J Cardiovasc Pharmacol       Date:  2012-02       Impact factor: 3.105

Review 4.  An eicosanoid-centric view of atherothrombotic risk factors.

Authors:  Scott Gleim; Jeremiah Stitham; Wai Ho Tang; Kathleen A Martin; John Hwa
Journal:  Cell Mol Life Sci       Date:  2012-04-11       Impact factor: 9.261

5.  The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice.

Authors:  Lindsey B Gano; Anthony J Donato; Hamza M Pasha; Christopher M Hearon; Amy L Sindler; Douglas R Seals
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-10-17       Impact factor: 4.733

6.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

7.  Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine.

Authors:  A Zembowicz; S L Jones; K K Wu
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  Differential inhibitory effects of isosorbide dinitrate and its mononitrate metabolites on platelet aggregation and thromboxane formation.

Authors:  P H Rolland; J Sampol; B Lacarelle; D Arnoux; F Leca; E Gueydon; J P Cano
Journal:  Pharm Res       Date:  1985-03       Impact factor: 4.200

9.  Relationship between serum levels of triglycerides and vascular inflammation, measured as COX-2, in arteries from diabetic patients: a translational study.

Authors:  Antonio Gordillo-Moscoso; Emilio Ruiz; Manuel Carnero; Fernando Reguillo; Enrique Rodriguez; Teresa Tejerina; Santiago Redondo
Journal:  Lipids Health Dis       Date:  2013-05-03       Impact factor: 3.876

10.  Ginger extract enhances antioxidant ability and immunity of layers.

Authors:  Shengying An; Guanzhong Liu; Xin Guo; Yahui An; Renyu Wang
Journal:  Anim Nutr       Date:  2019-06-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.